Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Larry Meneely who wrote (1360)	2/24/2000 12:14:00 AM
From: chirodoc	Respond to of 2344

Market size for Theratope, BLP 25 by: csbiomajor 2/23/00 9:19 pm The company's estimates for sales of Theratope and BLP 25 once successfully launched and without any use in the preventive role are $400 million and $1 billion US, repectively. But in my opinion, by 2005 people will be suing their HMO's to pay for them as preventives.

To: Larry Meneely who wrote (1360)	2/24/2000 2:48:00 PM
From: Larry Meneely	Read Replies (1) \| Respond to of 2344

Research Information: Cancer Vaccines " Full Text of this Article Reprint (PDF) Version of this Article Similar articles found in: JCO Online PubMed PubMed Citation Search Medline for articles by: Greten, T. F. \|\| Jaffee, E. M. Alert me when: new articles cite this article Download to Citation Manager Journal of Clinical Oncology, Vol 17, Issue 3 (March), 1999: 1047 ¸ 1999 American Society for Clinical Oncology -------------------------------------------------------------------------------- BIOLOGY IN NEOPLASIA Cancer Vaccines Tim F. Greten, Elizabeth M. Jaffee From the Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD. Address reprint requests to Elizabeth M. Jaffee, MD, Department of Oncology, The Johns Hopkins University School of Medicine, 720 Rutland Ave, Ross 350, Baltimore, MD 21205-2196; email ejaffee@welchlink.welch.jhu.edu. ABSTRACT It has been more than 100 years since the first reported attempts to activate a patient's immune system to eradicate developing cancers. Although a few of the subsequent vaccine studies demonstrated clinically significant treatment effects, active immunotherapy has not yet become an established cancer treatment modality. Two recent advances have allowed the design of more specific cancer vaccine approaches: improved molecular biology techniques and a greater understanding of the mechanisms involved in the activation of T cells. These advances have resulted in improved systemic antitumor immune responses in animal models. Because most tumor antigens recognized by T cells are still not known, the tumor cell itself is the best source of immunizing antigens. For this reason, most vaccine approaches currently being tested in the clinics use whole cancer cells that have been genetically modified to express genes that are now known to be critical mediators of immune system activation. In the future, the molecular definition of tumor-specific antigens that are recognized by activated T cells will allow the development of targeted antigen-specific vaccines for the treatment of patients with cancer. -------------------------------------------------------------------------------- HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH SEARCH RESULT ¸ 1999 American Society of Clinical Oncology. " jco.org I have more good stuff to come - later. Larry Meneely